1.Name and nature of the underlying security (if preferred shares, the terms
and conditions of issuance shall also be indicated, e.g., dividend yield):
   Partnership interests in CDIB Cross Border Innovation Fund II LP
   (hereinafter referred to as “CCBI Fund II”)
2.Date of occurrence of the event:2025/07/28
3.No., unit price, and monetary amount of the transaction:
   No., unit price: Not applicable,
   Total monetary amount of the transaction: The transaction amount will
   be increased by US$193,221, bringing the total transaction amount to
   US$816,364.
4.Counterparty to the trade and its relationship to the company (if the
trading counterparty is a natural person and not a related party of the
company, its name is not required to be disclosed):
   Counterpart：CCBI Fund II
   Its relationship to the Company：Related party disclosed in financial
   statements
5.Where the counterparty to the trade is a related party, an announcement
shall also be made of the reason for choosing the related party as trading
counterparty and the identity of the previous owner, including its
relationship with the company and the trading counterparty, the price of the
ownership transfer, and date of transfer:
   A fund raised by the Group and Partner(s); No previous transfer
6.Where the owner of the underlying securities within the past five years
has been a related party of the company, an announcement shall also include
the dates and prices of acquisition and disposal by the related party and
its relationship with the company at the time:N/A
7.Matters related to the creditor’s rights currently being disposed of
(including type of collateral of the disposed creditor’s rights; if the
creditor’s rights are creditor’s rights over a related party, the name of
the related party and the book amount of such creditor’s rights currently
being disposed of must also be announced):N/A
8.Profit (or loss) from the disposal (not applicable in cases of acquisition
of securities) (where originally deferred, the status or recognition shall
be stated and explained):N/A
9.Terms of delivery or payment (including payment period and monetary
amount), restrictive covenants in the contract, and other important
stipulations: Payment will be delivered per the fund-related agreements.
10.The manner in which the current transaction was decided, the reference
basis for the decision on price, and the decision-making unit:
   The manner in which the current transaction was decided, the reference
   basis for the decision on price：Per fund-related agreements.
   The decision-making department：The Board.
11.Net worth per share of company of the underlying securities acquired or
disposed of:N/A
12.The discrepancy between the reference price of private placement company
and the transaction amount per share is 20 percent or more:N/A
13.Current cumulative no., amount, and shareholding ratio of the securities
being traded (including the current transaction) as of the date of
occurrence and status of any restriction of rights (e.g.,pledges):
   (1)Current cumulative volume: N/A.
   (2)Amount of the securities being traded: US$816,364.
   (3)Shareholding ratio: 1%
   (4)Status of any restriction of rights: None.
14.Privately placed securities (including the current transaction) as a
percentage of total assets of the company and shareholder’s equity of the
parent company on the latest financial statements, and the operating capital
on the latest financial statements as of the date of occurrence:
   (1) to the total assets: 0.01%
   (2) to the shareholder's equity:0.01%
   (3) The operating capital: N/A
15.Broker and broker's fee:N/A
16.Concrete purpose or use of the acquisition or disposition:
   For the needs of investment portfolio expansion.
17.Whether the directors expressed any objection to the present transaction:No
18.Whether the trading counterparty is a related party:Yes
19.Date of approval by board of directors:2025/07/28
20.Recognition date by supervisors or approval date by audit committee:
   N/A, the procedure under Article 45 of the Financial Holding Company Act
   shall apply.
21.Whether the CPA issued an opinion on the unreasonableness of the current
transaction:No
22.Name of the CPA firm:Diwan & Company
23.Name of the CPA:Jui-Wen Lu, CPA
24.License no.of the CPA:No. Jin-Guan-Cheng-Shen-1000047855
25.Any other matters that need to be specified:
   1)The full name of “CCIA” is “CDIB Capital Innovation Advisors
      Corporation”.
   2)On December 14, 2023, the board of CCIA approved and announced its
      intention to participate in CDIB Cross Border Innovation Fund II LP
      (“CCBI Fund II”, formerly tentatively named CDIB Cross Border
      Innovation Fund) with an investment cap of the lower of 1% of the fund
      or US$1 million. On August 8, 2024, CCIA invested US$623,143 in CCBI
      Fund II. In order to maintain a 1% investment ratio in the Fund and
      within the previously approved investment cap, the board of CCIA has
      further approved to increase its investment by US$193,221, bringing
      the current total investment amount to US$ 816,364.